Source - LSE Regulatory
RNS Number : 9168R
Tissue Regenix Group PLC
06 March 2023
 

Tissue Regenix Group plc

('Tissue Regenix' or the 'Company')

 

Notice of results and Investor presentation

 

Tissue Regenix (AIM: TRX), the regenerative medical device company, will announce its final results for the year ended 31 December 2022 on Tuesday 21 March 2023.

 

Investor Briefing

Daniel Lee, Chief Executive Officer, and David Cocke, Chief Financial Officer, will host a live online presentation relating to the final results via the Investor Meet Company platform at 1.30pm on Thursday 23 March 2023. The presentation is open to all existing and potential shareholders.

 

Investors can sign up to Investor Meet Company for free and register for the presentation here: https://www.investormeetcompany.com/tissue-regenix-group-plc/register-investor

 

Investors who already follow Tissue Regenix on the Investor Meet Company platform will be de facto invited.

 

For more information:

 

Tissue Regenix Group plc

www.tissueregenix.com

David Cocke, Chief Financial Officer

Via Walbrook PR



finnCap Ltd (Nominated Adviser and Broker) 


Emily Watts/Geoff Nash/George Dollemore - Corporate Finance


Nigel Birks/Harriet Ward - ECM


 


Walbrook PR (Financial PR & IR)

Tel: +44(0)20 7933 8780

Alice Woodings / Lianne Applegarth

TissueRegenix@walbrookpr.com

 

 

 

About Tissue Regenix (www.tissueregenix.com)

Tissue Regenix is a leading medical device company in the field of regenerative medicine. The Company's patented decellularisation technology ('dCELL®') removes DNA and other cellular material from animal and human soft tissue, leaving an acellular tissue scaffold which is not rejected by the patient's body and can then be used to repair diseased or damaged body structures. Current applications address many critical clinical needs in sports medicine, foot and ankle and wound care.

 

In August 2017, Tissue Regenix acquired CellRight Technologies®, a biotech company that specialises in regenerative medicine and is dedicated to the development of high quality, innovative tissue scaffolds, which can enhance healing opportunities in defects created by trauma and disease. CellRight®'s human tissue products may be used in spine, trauma, general orthopaedic, dental and ophthalmological surgical procedures.

 

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
NORFLFITVTIVIIV
Find out how to deal online from £1.50 in a SIPP, ISA or Dealing account. AJ Bell logo

Related Charts

Tissue Regenix Group PLC (TRX)

+0.50p (+0.81%)
delayed 15:57PM